Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab

Tiziana Life Sciences (TLSA) announced dosing has commenced at Johns Hopkins University, JHU, Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis, na-SPMS. Other active clinical sites in the study include Brigham and Women’s Hospital, BWH, and MS Center at Yale Medical Center. The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis characterized by progressive neurological decline without relapses.